Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa

Next Previous
Trial Profile

Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxone (Primary)
  • Indications Bulimia nervosa
  • Focus Therapeutic Use
  • Sponsors Opiant Pharmaceuticals

Most Recent Events

  • 21 Feb 2019 Primary endpoint (Number of binging days from baseline to Week 8) has not been met, according to an Opiant Pharmaceuticals media release.
  • 21 Feb 2019 Top-line results presented in the media release.
  • 05 Nov 2018 According to an Opiant Pharmaceuticals media release, Last Patient, Last Visit (LPLV) occurred on November 2, 2018 in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top